Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLD-101
- Development stage
- Unknown
- Lead developer
- Calidi Biotherapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intratumoral
01
Overview
CLD-101 (NSC-CRAd-S-pk7) is an investigational cell-based oncolytic virotherapy developed for the treatment of high-grade gliomas. It consists of neural stem cells (NSCs) that serve as a delivery vehicle for a conditionally replicating oncolytic adenovirus (CRAd). The adenovirus is engineered with a survivin promoter (S) to drive replication specifically in cancer cells and a pk7 fiber modification to enhance viral entry into tumor cells. The NSCs are progenitor cells capable of migrating through the brain parenchyma to reach invasive tumor cells, effectively bypassing the blood-brain barrier. Once at the tumor site, the NSCs release the oncolytic virus, which selectively infects and lyses glioma cells, potentially eliciting a systemic anti-tumor immune response. The therapy was originally developed at Northwestern University and is currently licensed to Calidi Biotherapeutics.
- Other names
- NeuroNovaNSC-delivered CRAd-Survivin-pk7
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on CLD-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLD-101.